Skip to main content

Table 1 Frequency of treatment-emergent adverse events (TEAEs) from baseline to treatment endpoint by treatment group

From: A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder

Event

ATX + MPH N= 9 n(%)

ATX + PBO N= 12 n(%)

Initial insomnia

1 (11.1)

2 (16.7)

Rash

1 (11.1)

0 (0.0)

GI discomfort

1 (11.1)

0 (0.0)

Cardiac SE

1 (11.1)

0 (0.0)

Toothache

1 (11.1)

0 (0.0)

Vomiting

1 (11.1)

2 (16.7)

Abdominal pain

0 (0.0)

1 (8.3)

BP Increase

0 (0.0)

1 (8.3)

Hand fracture

0 (0.0)

1 (8.3)

Headache

0 (0.0)

2 (16.7)

Insomnia

0 (0.0)

1 (8.3)

Irritability

0 (0.0)

1 (8.3)

Nausea

0 (0.0)

2 (16.7)

Rhinitis

0 (0.0)

2 (16.7)

  1. Key: GI, gastrointestinal; SE, supraventricular extrasystoles; BP, blood pressure
  2. No significant differences were found between groups.
Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000